Baupost Group LLC MA Has $80.09 Million Position in Solventum Corporation $SOLV

Key Points

• Baupost Group LLC reduced its stake in Solventum Corporation by 27.2%, selling 393,060 shares and now holds approximately 1,053,240 shares, making it 15th in the firm’s portfolio.
• Analyst ratings for Solventum have varied, with some upgrades including a target price increase from $80.00 to $103.00 by Morgan Stanley, while others downgraded the stock from "strong-buy" to "buy."
• Solventum's recent earnings reported an EPS of $1.69, exceeding analyst expectations, with revenue growth of 3.8% from the previous year, reflecting a strong financial performance.

Baupost Group LLC MA lowered its stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 27.2% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,053,240 shares of the company's stock after selling 393,060 shares during the quarter. Solventum comprises 2.3% of Baupost Group LLC MA's portfolio, making the stock its 15th largest holding. Baupost Group LLC MA owned approximately 0.61% of Solventum worth $80,088,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Clarity Asset Management Inc. acquired a new position in shares of Solventum during the fourth quarter worth approximately $25,000. Rossby Financial LCC acquired a new position in shares of Solventum in the first quarter valued at $25,000. Strengthening Families & Communities LLC raised its stake in shares of Solventum by 376.8% in the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock valued at $25,000 after purchasing an additional 260 shares in the last quarter. Raiffeisen Bank International AG acquired a new position in shares of Solventum in the fourth quarter valued at $29,000. Finally, Colonial Trust Co SC raised its stake in shares of Solventum by 240.7% in the fourth quarter. Colonial Trust Co SC now owns 511 shares of the company's stock valued at $34,000 after purchasing an additional 361 shares in the last quarter.

Solventum Trading Down 0.3%

Solventum stock traded down $0.24 during mid-day trading on Thursday, hitting $72.65. The stock had a trading volume of 1,036,911 shares, compared to its average volume of 1,082,607. The stock has a 50-day simple moving average of $73.77 and a two-hundred day simple moving average of $72.84. The stock has a market capitalization of $12.60 billion, a PE ratio of 33.64, a P/E/G ratio of 1.77 and a beta of 0.52. Solventum Corporation has a 12 month low of $60.01 and a 12 month high of $85.92. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The firm had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same quarter in the prior year, the firm posted $1.56 earnings per share. The company's quarterly revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, sell-side analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Analyst Ratings Changes

SOLV has been the subject of a number of recent research reports. Wells Fargo & Company upped their target price on Solventum from $75.00 to $79.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. KeyCorp began coverage on Solventum in a research report on Friday, June 6th. They issued a "sector weight" rating on the stock. Piper Sandler reiterated an "overweight" rating and issued a $94.00 price target (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. Finally, Wall Street Zen cut Solventum from a "strong-buy" rating to a "buy" rating in a research report on Sunday. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $85.75.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.